Kenneth Hoberman Sells 13,547 Shares of Stemline Therapeutics Inc (STML) Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 13,547 shares of the company’s stock in a transaction dated Tuesday, January 8th. The shares were sold at an average price of $10.15, for a total transaction of $137,502.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kenneth Hoberman also recently made the following trade(s):

  • On Monday, November 26th, Kenneth Hoberman sold 26,296 shares of Stemline Therapeutics stock. The shares were sold at an average price of $11.85, for a total transaction of $311,607.60.

Shares of STML stock opened at $9.89 on Monday. Stemline Therapeutics Inc has a one year low of $7.82 and a one year high of $20.55. The company has a market capitalization of $329.14 million, a PE ratio of -3.36 and a beta of 0.78.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.06). Research analysts anticipate that Stemline Therapeutics Inc will post -2.81 earnings per share for the current year.

Several research firms have weighed in on STML. ValuEngine upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 23rd. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 21st. Roth Capital set a $33.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 14th. BidaskClub lowered shares of Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, November 2nd. Finally, Piper Jaffray Companies set a $20.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Friday, December 21st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.00.

Large investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in shares of Stemline Therapeutics by 48.9% in the 2nd quarter. Rhumbline Advisers now owns 38,788 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 12,732 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Stemline Therapeutics by 8.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 59,025 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 4,700 shares during the last quarter. BlackRock Inc. grew its position in shares of Stemline Therapeutics by 17.9% in the 2nd quarter. BlackRock Inc. now owns 1,852,820 shares of the biopharmaceutical company’s stock valued at $29,739,000 after buying an additional 281,394 shares during the last quarter. BlueMountain Capital Management LLC purchased a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $137,000. Finally, Bank of America Corp DE grew its position in shares of Stemline Therapeutics by 97.8% in the 2nd quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 10,159 shares during the last quarter. 64.20% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2019/01/14/kenneth-hoberman-sells-13547-shares-of-stemline-therapeutics-inc-stml-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Featured Article: Initial Public Offering (IPO)

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit